Showing results (141-150 of 172) with videos related to

Sort By:
Pageof 18
Arthritis and Rheumatism|June 12, 1999
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trialP J Clements, D E Furst, W K Wong, et al.
Seminars in Arthritis and Rheumatism|February 24, 2004
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements, James R Seibold, Daniel E Furst, et al.
Annals of Internal Medicine|June 3, 2000
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trialJ R Seibold, J H Korn, R Simms, et al.
Arthritis and Rheumatism|December 30, 2006
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192Christopher P Denton, Peter A Merkel, Daniel E Furst, et al.
Rheumatology (Oxford, England)|June 27, 2001
Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trialD E Furst, P J Clements, W K Wong, et al.
Arthritis and Rheumatism|November 18, 2000
Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trialP J Clements, E L Hurwitz, W K Wong, et al.
Arthritis and Rheumatism|March 27, 2001
The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trialP J Clements, W K Wong, E L Hurwitz, et al.
Annals of the Rheumatic Diseases|September 1, 2010
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trialMarco Matucci-Cerinic, Christopher P Denton, Daniel E Furst, et al.
Arthritis and Rheumatism|October 2, 2002
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenonPeter A Merkel, Karen Herlyn, Richard W Martin, et al.
Arthritis and Rheumatism|December 14, 2004
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonistJ H Korn, M Mayes, M Matucci Cerinic, et al.
Pageof 18